Zai Lab Ltd- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Zai Lab Ltd 公司

Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.

Zai Lab Ltd簡介



公司代碼ZLAB

公司名稱Zai Lab Ltd

上市日期Sep 28, 2020

CEODu (Ying)

員工數量1869

證券類型Depository Receipt

年結日Sep 28

公司地址Building B, 899 Halei Road, Pudong

城市SHANGHAI

上市交易所NASDAQ OMX - NASDAQ BASIC

國家China

郵編201203

電話862161632588

網址https://www.zailaboratory.com/

公司代碼ZLAB

上市日期Sep 28, 2020

CEODu (Ying)

Zai Lab Ltd公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Joshua L. Smiley

President, Chief Operating Officer

117.60K

+22.60%

Dr. John David Diekman, Ph.D.

Lead Independent Director

99.77K

+10.86%

Mr. William David (Bill) Lis

Independent Director

35.11K

-8.50%

Dr. Yajing Chen, Ph.D.

Chief Financial Officer

19.15K

-4.46%

Dr. Ying (Samantha) Du, Ph.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

Ms. Leung (Nisa Bernice) Wing-Yu

Independent Director

--

Mr. Peter Karl Wirth, J.D.

Independent Director

--

Mr. Leon Oliver (Lonnie) Moulder, Jr.

Independent Director

--

Mr. Frazor Titus Edmondson, J.D.

Company Secretary, Chief Legal Officer

--

Mr. Scott W. Morrison, CPA

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Joshua L. Smiley

President, Chief Operating Officer

117.60K

+22.60%

Dr. John David Diekman, Ph.D.

Lead Independent Director

99.77K

+10.86%

Mr. William David (Bill) Lis

Independent Director

35.11K

-8.50%

Dr. Yajing Chen, Ph.D.

Chief Financial Officer

19.15K

-4.46%

Dr. Ying (Samantha) Du, Ph.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

Ms. Leung (Nisa Bernice) Wing-Yu

Independent Director

--

收入明細

單位: USD更新時間: 4月6日週一

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

業務USD

名稱

營收

佔比

ZEJULA

189.04M

41.35%

VYVGART

94.20M

20.60%

NUZYRA

60.84M

13.31%

Optune

48.33M

10.57%

QINLOCK

35.61M

7.79%

其他

29.17M

6.38%

地區USD

名稱

營收

佔比

China (Mainland)

460.16M

0.00%

業務

地區

業務USD

名稱

營收

佔比

ZEJULA

189.04M

41.35%

VYVGART

94.20M

20.60%

NUZYRA

60.84M

13.31%

Optune

48.33M

10.57%

QINLOCK

35.61M

7.79%

其他

29.17M

6.38%

股東統計

更新時間: 5月14日週四

持股股東

股東類型

持股股東

佔比

RTW Investments L.P.

6.19%

RA Capital Management, LP

5.11%

Norges Bank Investment Management (NBIM)

3.42%

Frazier Life Sciences Management, L.P.

1.69%

ClearBridge Investments, LLC

1.61%

其他

81.97%

持股股東

佔比

RTW Investments L.P.

6.19%

RA Capital Management, LP

5.11%

Norges Bank Investment Management (NBIM)

3.42%

Frazier Life Sciences Management, L.P.

1.69%

ClearBridge Investments, LLC

1.61%

其他

81.97%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

11.71%

Investment Advisor

5.60%

Venture Capital

5.36%

Hedge Fund

4.22%

Sovereign Wealth Fund

3.42%

Individual Investor

1.91%

Private Equity

1.69%

Research Firm

1.50%

Pension Fund

0.05%

其他

64.54%

機構持股



更新時間: 4月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2026Q4

280

37.42M

42.38%

--

2026Q1

352

37.82M

33.67%

-10.78M

2025Q4

370

44.73M

39.84%

-12.84M

2025Q3

372

46.61M

41.70%

-15.37M

2025Q2

394

60.58M

54.15%

-11.96M

2025Q1

453

59.51M

53.68%

-14.18M

2024Q4

446

60.80M

55.47%

-4.29M

2024Q3

439

51.45M

51.99%

-10.14M

2024Q2

454

47.04M

47.66%

-14.67M

2024Q1

465

46.22M

46.47%

-13.77M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

RTW Investments L.P.

6.96M

6.14%

+4.67M

+203.71%

Dec 31, 2025

Norges Bank Investment Management (NBIM)

3.84M

3.39%

+3.84M

--

Dec 31, 2025

Frazier Life Sciences Management, L.P.

1.90M

1.68%

+275.00K

+16.90%

Dec 31, 2025

ClearBridge Investments, LLC

1.81M

1.59%

-1.71M

-48.63%

Dec 31, 2025

Citadel Advisors LLC

1.69M

1.49%

+700.80K

+71.00%

Dec 31, 2025

Fidelity Management & Research Company LLC

1.44M

1.27%

-2.84M

-66.32%

Dec 31, 2025

Baron Capital Management, Inc.

1.42M

1.25%

+46.76K

+3.41%

Dec 31, 2025

Adar1 Capital Management LLC

1.25M

1.1%

+377.74K

+43.48%

Dec 31, 2025

Du (Ying Samantha)

1.06M

0.94%

+145.74K

+15.88%

Mar 11, 2026

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Tema Oncology ETF

1.67%

ALPS Medical Breakthroughs ETF

1.19%

Virtus LifeSci Biotech Products ETF

0.97%

Invesco Golden Dragon China ETF

0.58%

National Security Emerging Markets Index ETF

0.39%

iShares Biotechnology ETF

0.18%

Capital Group New Geography Equity ETF

0.15%

ProShares Ultra Nasdaq Biotechnology

0.12%

Invesco Nasdaq Biotechnology ETF

0.12%

ActivePassive International Equity ETF

0.03%

Tema Oncology ETF

佔比1.67%

ALPS Medical Breakthroughs ETF

佔比1.19%

Virtus LifeSci Biotech Products ETF

佔比0.97%

Invesco Golden Dragon China ETF

佔比0.58%

National Security Emerging Markets Index ETF

佔比0.39%

iShares Biotechnology ETF

佔比0.18%

Capital Group New Geography Equity ETF

佔比0.15%

ProShares Ultra Nasdaq Biotechnology

佔比0.12%

Invesco Nasdaq Biotechnology ETF

佔比0.12%

ActivePassive International Equity ETF

佔比0.03%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據